(300) Optimization of amiloride-loaded nanoparticles for podocyte injury in glomerular disease.

Introduction: Glomerular disease can lead to end-stage renal disease1.Podocytes are cells injured in glomerular disease when exposed to plasminogen activated by urokinase-type plasminogen activator (uPa)2,3.Amiloride,a diuretic blocks sodium channels in kidneys and inhibits uPa4.Polymeric mesoscale nanoparticles (MNPs),300-500 nm selectively target the kidneys5.While MNPs have shown to localize to tubular epithelial cells, our preliminary work found that they are taken up by podocytes in glomerular disease.Thus, we aim to formulate amiloride-encapsulating MNPs to inhibit uPa in glomerular disease.